entertainment -WSS

entertainment

author：explore 2025-10-01 15:28:01 - browse：71

Two people run on the sugar-phosphate backbone of DNA while holding base pairs — in the lab coverage from STAT — Adobe

LONDON — Widespread genetic testing as well as the development of cutting-edge, customized genetic therapies have opened the door to treating many more inherited conditions than previously possible. A few recent cases, in which bespoke medicines were created for children with exceedingly rare mutations, have raised hopes for furthering the approach.

Now, researchers and government agencies in the U.K. are trying to figure out the nitty-gritty to replicate those early one-off successes for as many patients as possible — what sort of preclinical testing a tailor-made treatment needs to go through before being used, what regulatory thresholds each treatment needs to clear, and how to pay for these therapies.

“A lot of the barriers are no longer scientific — we can make these drugs,” said Matthew Wood, a professor of pediatrics at the University of Oxford. “It’s more about, can we make them at a cost that is reasonable enough? And can we get the regulators to reduce the barriers to doing this so that when a patient shows up, you can actually make a drug quickly enough to benefit that patient, rather than it costing huge amounts of money and taking two or three years to do it?”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Australia's humpback populations rebound raising hopes of marine scientists

focus

WSS

FDA has safety concerns on CRISPR

Russia says it foiled Ukrainian drone attack on Moscow as Kyiv's counteroffensive grinds on

Physician subsidies by hospitals soar in wake of No Surprises Act

Chimpanzees, like humans and whales, get menopause: Study

Can food be medicine? And other questions about a new push

Listen: Biogen's messy board & Laronde's data problem

hotspot

entertainment

focus

In age of alternative facts, a scholarly course on calling out crap

Why Sanofi got shellacked over its spinoff

After affirmative action ruling, medical educators look to 'holistic review'

Did the public have the right to know Arthur Ashe had AIDS?

BioMarin wins approval for gene therapy to treat hemophilia A

Russia says it foiled Ukrainian drone attack on Moscow as Kyiv's counteroffensive grinds on

Jerome Adams on the need for new antivirals for Covid

Pfizer's Covid pill remains 89% effective in final analysis, company says

Virginia high school admissions case could be legal follow

Australia's humpback populations rebound raising hopes of marine scientists

hotspot

Grail is spending more than ever lobbying Congress

FDA approves Eli Lilly ulcerative colitis treatment Omvoh

Meta's Zuckerberg and Chan on track to put $50 billion into science

STAT Wunderkinds: Ruey Hu's digital tools for parsing research

Diversifying clinical trials isn't enough to close racial gaps: study

Doctor appointment wait times are getting worse

Wikipedia

hotspot

focus

knowledge